MARKETSSTORY 528· JULY 6, 2026

Junshi Biosciences and Fosun Wanbang Strike Licensing Deal on IL-17A Inhibitor Roconkibart in Greater China

Junshi Biosciences has entered a licensing collaboration with Fosun Wanbang to develop and commercialize roconkibart across the Greater China Region. Roconkibart targets interleukin-17A, a cytokine tied to inflammatory disease. The…

NDNewsDialy Desk2 MIN READ

SOURCE

globenewswire.com

← PREVIOUS STORY 527Noah Holdings Introduces "Noah World Model" Framework in 12th CIO Report, Citing AI Value Realization and Global Asset Repricing NEXT STORY 529 →Equitable Bank Takes Over as Performance Guarantor of Eagle Credit Card Trust After PC Bank Deal Closes

Keep reading

More from the desk.

04MARKETS

Pershing Square narrows its book to three names: Uber, Brookfield, and Microsoft

Concentration, in portfolio management, means putting most of a fund's capital into a small number of positions rather than spreading it across many names. Pershing Square has organized its

markets1 MIN

22MARKETS

Nintendo shares jump 7% as Pokémon Pokopia tops 5 million sales

Five million copies sold is the number that moved Nintendo's stock. Nintendo shares jumped 7% after Pokémon Pokopia crossed that threshold. The result carries extra weight because rising memory prices

markets1 MIN

84MARKETS

Nvidia reportedly plans a $500 billion off-balance sheet vehicle

A half-trillion-dollar corporate structure designed to sit outside a company's main financial filings is reportedly being prepared for disclosure. That arrangement relies on a special purpose vehicle, a separate legal entity set up so its…

markets2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk